Cargando…
Clinical factors predicting drug-induced liver injury due to flucloxacillin
OBJECTIVES: Drug-induced liver injury (DILI) is a serious adverse reaction due to flucloxacillin. The pathogenesis is not fully understood. Female sex, age over 60 years, and a longer treatment duration have been suggested to be predisposing factors. Carriers of HLA-B*57:01 have an 80-fold increased...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254585/ https://www.ncbi.nlm.nih.gov/pubmed/30538582 http://dx.doi.org/10.2147/DHPS.S178394 |
_version_ | 1783373748531888128 |
---|---|
author | Lindh, Mikaela Hallberg, Pär Yue, Qun-Ying Wadelius, Mia |
author_facet | Lindh, Mikaela Hallberg, Pär Yue, Qun-Ying Wadelius, Mia |
author_sort | Lindh, Mikaela |
collection | PubMed |
description | OBJECTIVES: Drug-induced liver injury (DILI) is a serious adverse reaction due to flucloxacillin. The pathogenesis is not fully understood. Female sex, age over 60 years, and a longer treatment duration have been suggested to be predisposing factors. Carriers of HLA-B*57:01 have an 80-fold increased risk, but due to the rarity of the reaction, testing of all patients is not cost-effective. We aimed to validate and detect clinical risk factors for flucloxacillin DILI. METHODS: Clinical characteristics of flucloxacillin-treated patients with (n=50) and without DILI (n=2,330) were compared in a retrospective case control study. Cases were recruited from the Swedish database of spontaneously reported adverse drug reactions. Treated controls were selected from the Swedish Twin Registry. Statistical comparisons were made using chi-squared test and logistic regression. The significance threshold was set to P<0.00357 to correct for multiple comparisons. Reliable variables were tested in a multiple regression model. RESULTS: DILI was associated with female sex, OR 2.79, 95% CI 1.50–5.17, P=0.0011, and with a history of kidney stones, OR 5.51, 95% CI 2.21–13.72, P=0.0003. Cases were younger than controls, OR per increase in years 0.91, 95% CI 0.88–0.94, P<0.0001, probably due to selection bias. No difference in treatment duration was detected, OR 1.03, 95% CI 0.98–1.08, P=0.1790. CONCLUSION: We established female sex as a risk factor for flucloxacillin-induced DILI, and a history of kidney stones was identified as a potential risk factor. Clinical risk factors for flucloxacillin-induced DILI could be used to indicate whom to test for HLA-B*57:01 before treatment. |
format | Online Article Text |
id | pubmed-6254585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62545852018-12-11 Clinical factors predicting drug-induced liver injury due to flucloxacillin Lindh, Mikaela Hallberg, Pär Yue, Qun-Ying Wadelius, Mia Drug Healthc Patient Saf Original Research OBJECTIVES: Drug-induced liver injury (DILI) is a serious adverse reaction due to flucloxacillin. The pathogenesis is not fully understood. Female sex, age over 60 years, and a longer treatment duration have been suggested to be predisposing factors. Carriers of HLA-B*57:01 have an 80-fold increased risk, but due to the rarity of the reaction, testing of all patients is not cost-effective. We aimed to validate and detect clinical risk factors for flucloxacillin DILI. METHODS: Clinical characteristics of flucloxacillin-treated patients with (n=50) and without DILI (n=2,330) were compared in a retrospective case control study. Cases were recruited from the Swedish database of spontaneously reported adverse drug reactions. Treated controls were selected from the Swedish Twin Registry. Statistical comparisons were made using chi-squared test and logistic regression. The significance threshold was set to P<0.00357 to correct for multiple comparisons. Reliable variables were tested in a multiple regression model. RESULTS: DILI was associated with female sex, OR 2.79, 95% CI 1.50–5.17, P=0.0011, and with a history of kidney stones, OR 5.51, 95% CI 2.21–13.72, P=0.0003. Cases were younger than controls, OR per increase in years 0.91, 95% CI 0.88–0.94, P<0.0001, probably due to selection bias. No difference in treatment duration was detected, OR 1.03, 95% CI 0.98–1.08, P=0.1790. CONCLUSION: We established female sex as a risk factor for flucloxacillin-induced DILI, and a history of kidney stones was identified as a potential risk factor. Clinical risk factors for flucloxacillin-induced DILI could be used to indicate whom to test for HLA-B*57:01 before treatment. Dove Medical Press 2018-11-21 /pmc/articles/PMC6254585/ /pubmed/30538582 http://dx.doi.org/10.2147/DHPS.S178394 Text en © 2018 Lindh et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Lindh, Mikaela Hallberg, Pär Yue, Qun-Ying Wadelius, Mia Clinical factors predicting drug-induced liver injury due to flucloxacillin |
title | Clinical factors predicting drug-induced liver injury due to flucloxacillin |
title_full | Clinical factors predicting drug-induced liver injury due to flucloxacillin |
title_fullStr | Clinical factors predicting drug-induced liver injury due to flucloxacillin |
title_full_unstemmed | Clinical factors predicting drug-induced liver injury due to flucloxacillin |
title_short | Clinical factors predicting drug-induced liver injury due to flucloxacillin |
title_sort | clinical factors predicting drug-induced liver injury due to flucloxacillin |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254585/ https://www.ncbi.nlm.nih.gov/pubmed/30538582 http://dx.doi.org/10.2147/DHPS.S178394 |
work_keys_str_mv | AT lindhmikaela clinicalfactorspredictingdruginducedliverinjuryduetoflucloxacillin AT hallbergpar clinicalfactorspredictingdruginducedliverinjuryduetoflucloxacillin AT yuequnying clinicalfactorspredictingdruginducedliverinjuryduetoflucloxacillin AT wadeliusmia clinicalfactorspredictingdruginducedliverinjuryduetoflucloxacillin |